阿托伐他汀与瑞舒伐他汀对冠心病患者的疗效与安全性对比观察

目的:对比分析阿托伐他汀与瑞舒伐他汀在冠心病患者中应用的疗效与安全性。方法:回顾性分析127例冠心病患者的临床资料,根据调脂药物的种类分为2组:阿托伐他汀组44例,基本用量20 mg·d^-1,用药(7.6±1.9)个月;瑞舒伐他汀组83例,基本用量10 mg·d^-1,用药(7.9±2.1)个月。分别统计治疗前、治疗后1,2,4,8,12周及末次复查时血脂水平,并记录药物不良反应。结果:患者接受药物治疗1周时各指标较治疗前均无明显变化(P>0.05);治疗2周时,两组TG、TC及LDL-C水平均较治疗前降低(P<0.05),但组间差异无统计学意义(P>0.05);药物治疗4,8,12周时,两组TG、TC及LDL-C较治疗前降低(P<0.05),瑞舒伐他汀组LDL-C水平低于阿托伐他汀组,而LDL-C的降幅和血脂达标率均高于阿托伐他汀组,差异均有统计学意义(P<0.05)。至末次复查,两组TG、TC及LDL-C均较基线水平显著降低(P<0.05),阿托伐他汀组LDL-C的降幅低于瑞舒伐他汀组(P<0.05)。两组共发生药物相关性不良反应9例,其中阿托伐他汀组4例(9.1%),瑞舒伐他汀组5例(6.0%),两组差异无统计学意义(P>0.05)。结论:瑞舒伐他汀和阿托伐他汀均于用药2周时表现出较好的调脂疗效,10 mg·d^-1瑞舒伐他汀的调脂疗效优于20 mg·d^-1阿托伐他汀,两药不良反应发生率均较低,安全性无明显差异。

Comparison of efficacy and safety between atorvastatin and rosuvastatin against coronary heart disease

OBJECTIVE To analyze the efficacy and safety of atorvastatin and rosuvastatin against coronary heart disease (CHD) comparatively.METHODS Patients with CHD (n=127) in our hospital were selected and analyzed retrospectively,divided into 2 groups according to the therapy drugs.Patients in atorvastatin group (n=44) were treated with basic dose of 20mg/d for (7.6±1.9) months,and patients in rosuvastatin group (n=83) were treated with basic dose of 10mg/d for (7.9±2.1) months.Blood lipid levels were reexamined and adverse reactions were recorded in all the patients before treatment,1,2,4,8,12 weeks after treatment.RESULTS After 1 week of treatment,the lipid levels in patients had small changes compared to baseline before treatment (P>0.05).After 2 weeks of treatment,the TG,TC and LDL-C of all the patients decreased relative to the baselines (P<0.05),but there was no significant difference between groups (P>0.05).After 4,8,12 weeks of treatment,the TG,TC and LDL-C of all the patients decreased compared to those before treatment (P<0.05),and LDL-C of the rosuvastatin group was lower than that of the atorvastatin group (P<0.05).Until the last reexamination,the LDL-C reduction and the rate of reaching the lipid standard of the rosuvastatin group were both higher than those of the atorvastatin group (P<0.05).There were 9 patients with drug adverse reaction in the treatment,4 in the atorvastatin group (9.1%) and 5 (6.0%) in the rosuvastatin group,with no significant difference between groups (P>0.05).CONCLUSION Both rosuvastatin and atorvastatin show lipid regulation effects in 2 weeks of treatment,while 10 mg rosuvastatin is superior to 20 mg atorvastatin in efficacy.Both statins show good security in this research.